Janus Henderson Group PLC Larimar Therapeutics, Inc. Transaction History
Janus Henderson Group PLC
- $188 Billion
- Q4 2024
A detailed history of Janus Henderson Group PLC transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 6,443,286 shares of LRMR stock, worth $20.6 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
6,443,286
Previous 5,566,855
15.74%
Holding current value
$20.6 Million
Previous $36.5 Million
32.5%
% of portfolio
0.01%
Previous 0.02%
Shares
18 transactions
Others Institutions Holding LRMR
# of Institutions
125Shares Held
66.8MCall Options Held
500KPut Options Held
61.2K-
Deerfield Management Company, L.P. (Series C) New York, NY21.2MShares$67.7 Million2.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$19.3 Million0.37% of portfolio
-
Blue Owl Capital Holdings LP New York, NY4.65MShares$14.8 Million7.6% of portfolio
-
Goldman Sachs Group Inc New York, NY4.15MShares$13.2 Million0.0% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$10.9 Million6.65% of portfolio
About Larimar Therapeutics, Inc.
- Ticker LRMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,269,200
- Market Cap $138M
- Description
- Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...